华法林基因检测在非瓣膜性心房颤动患者个体化抗凝中的应用
CSTR:
作者:
作者单位:

(1.扬州大学临床医学院,江苏 扬州225001;2.江苏省苏北人民医院心血管内科,江苏 扬州,225001)

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金青年基金(81800250);中国博士后科学基金第71批次面上资助二等(2022M711417);江苏省中医药科技发展计划(MS2023137);扬州市科技计划社会发展项目(YZ2023096)


Application of Warfarin genetic testing in individualized anticoagulation in patients with non-valvular atrial fibrillation
Author:
Affiliation:

(1.Clinical Medical College, Yangzhou University, Yangzhou 225001, Jiangsu Province, China;2.Department of Cardiology, Northern Jiangsu People′s Hospital, Yangzhou 225001, Jiangsu Province, China)

Fund Project:

This work was supported by National Natural Science Foundation of China for Young Scientists( 81800250), Second Prize of the 71st Batch of General Financial Aid from the China Postdoctoral Science Foundation (2022M711417), Project of Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan ( MS2023137) and Social Development Project of Yangzhou Science and Technology Plan (YZ2023096).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 评估华法林基因检测在非瓣膜性心房颤动患者抗凝治疗中的应用。方法 选择2021年1月至2023年1月在苏北人民医院门诊接受华法林治疗的非瓣膜性心房颤动患者。根据是否进行华法林基因检测,分为基因检测组和常规随访组。收集患者的临床资料并统计不良事件发生情况,比较两组患者的初始国际标准化比率(INR)值、达到治疗INR时间、达到稳态华法林剂量所需时间、不良反应事件发生情况及不同时间内两组患者INR在治疗范围的时间百分比(TTR)。采用SPSS 27.0软件进行数据分析。根据数据类型,组间比较分别采用t检验、Wilcoxon检验、χ2检验及Fisher精确概率法。结果 本研究共纳入患者200例,其中基因检测组患者110例,常规随访组患者90例。110例基因检测患者中,在CYP2C9 3位点,90.00%(99/110)为AA野生型,8.18%(9/110)为AC杂合型,1.82%(2/110)为CC纯合型;在VKORC1基因,86.36%(95/110)为AA突变纯合型,11.82%(13/110)为GA杂合型,1.82%(2/110)为GG突变纯合型。基因检测组发生小出血事件2例(1.81%),无大出血事件;常规随访组发生小出血事件6例(6.67%),大出血2例(2.22%)。两组患者在小出血和大出血事件的累积发生率,差异无统计学意义(P>0.05)。基因检测组达治疗INR值时间为(28.09±31.21)d,常规随访组为(45.47±45.33)d,差异有统计学意义(P<0.05)。基因检测组在最初1个月TTR高于常规随访组,差异有统计学意义(P<0.05);但在前3、6、12个月两组差异无统计学意义(P>0.05)。在INR<1.2和INR>3.5事件的发生率上,基因检测组的发生比例低于常规随访组,差异有统计学意义(P<0.05)。结论 基因检测能辨识个体对华法林的灵敏性,促使患者快速达到目标剂量并将INR维持在最佳治疗范围,进而有助于减少出血和栓塞等不良事件发生。

    Abstract:

    Objective To evaluate the application of Warfarin genetic testing in individualized anticoagulant therapy for patients with non-valvular atrial fibrillation (NVAF). Methods NVAF patients undergoing Warfarin treatment at the Outpatient Department of Northern Jiangsu People′s Hospital between January 2021 and January 2023 were enrolled. According to whether Warfarin genetic testing was performed, they were divided into a genetic testing group and a routine follow-up group. The clinical data were collected, and adverse events were statistically analyzed. The two groups were compared in initial international normalized ratio (INR), time to achieve therapeutic INR, time to reach stable warfarin dose, percentage of time INR in therapeutic range (TTR) at different times, and adverse reactions. SPSS 27.0 was used for statistical analysis. Data comparison between two groups was performed using t test, Wilcoxon test,χ2 test or Fisher exact test depending on data type. Results A total of 200 patients were enrolled in this study, includ-ing 110 patients in the genetic testing group and 90 in the routine follow-up group. In the genetic testing group, 90.00% (99/110) were of AA wild type, 8.18% (9/110) of AC heterozygous, and 1.82% (2/110) of CC homozygous at the CYP2C9 3 locus; 86.36% (95/110) of AA mutation homozygous, 11.82% (13/110) of GA heterozygous, and 1.82% (2/110) of GG mutation homozygous for the VKORC1 gene. Minor bleeding occurred in two patients (1.81%) in the genetic testing group without major bleeding, and minor bleeding occurred in six patients (6.67%) and major bleeding in two patients (2.22%) in the routine follow-up group. There was no significant difference in the cumulative incidence of minor and major bleeding between the two groups (P>0.05) The time to reach the therapeutic INR was (28.09±31.21)d in the genetic testing group, and (45.47±45.33)d in the routine follow-up group, with a statistically significant difference (P<0.05). At one month, TTR in the genetic testing group was higher than that in the routine follow-up group, with a statistically significant difference (P<0.05), but there was no significant difference between the two groups at 3,6 and 12 months. The gene testing group had a notably lower incidence rate of INR<1.2 events and INR>3.5 events than the routine follow-up group, with a statistically significant difference (P<0.05). Conclusion Genetic testing can identify individual sensitivity to Warfarin, helping patients to reach target doses quickly and maintain INR within the optimal therapeutic range and thereby reducing the adverse events such as bleeding and thromboses.

    参考文献
    相似文献
    引证文献
引用本文

钟晨露,朱业,顾翔.华法林基因检测在非瓣膜性心房颤动患者个体化抗凝中的应用[J].中华老年多器官疾病杂志,2025,24(6):417-421
DOI:10.11915/j. issn.1671-5403.2025.06.087

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-04-26
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-06-25
  • 出版日期:
文章二维码